减少慢性阻塞性肺疾病持续氧化应激负担的策略。
Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease.
机构信息
Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester Medical Center, Rochester, NY 14642, USA.
出版信息
Expert Rev Clin Pharmacol. 2012 May;5(3):293-309. doi: 10.1586/ecp.12.16.
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity globally, and its development is mainly associated with tobacco/biomass smoke-induced oxidative stress. Hence, targeting systemic and local oxidative stress with agents that can balance the antioxidant/redox system can be expected to be useful in the treatment of COPD. Preclinical and clinical trials have revealed that antioxidants/redox modulators can detoxify free radicals and oxidants, control expression of redox and glutathione biosynthesis genes, chromatin remodeling and inflammatory gene expression; and are especially useful in preventing COPD exacerbations. In this review, various novel approaches and problems associated with these approaches in COPD are reviewed.
摘要
慢性阻塞性肺疾病（COPD）是全球主要的致死和致残原因，其发展主要与烟草/生物燃料烟雾引起的氧化应激有关。因此，用能够平衡抗氧化/氧化还原系统的药物靶向全身和局部氧化应激有望对 COPD 的治疗有用。临床前和临床试验表明，抗氧化剂/氧化还原调节剂可以解毒自由基和氧化剂，控制氧化还原和谷胱甘肽生物合成基因、染色质重塑和炎症基因表达的表达；并且在预防 COPD 恶化方面特别有用。在这篇综述中，我们回顾了 COPD 中与这些方法相关的各种新方法和问题。
相似文献
1
Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease.减少慢性阻塞性肺疾病持续氧化应激负担的策略。
Expert Rev Clin Pharmacol. 2012 May;5(3):293-309. doi: 10.1586/ecp.12.16.
2
Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.慢性阻塞性肺疾病的药物和饮食抗氧化治疗。
Curr Med Chem. 2013;20(12):1496-530. doi: 10.2174/0929867311320120004.
3
Antioxidant therapies in COPD.慢性阻塞性肺疾病中的抗氧化疗法。
Int J Chron Obstruct Pulmon Dis. 2006;1(1):15-29. doi: 10.2147/copd.2006.1.1.15.
4
Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的肺和全身氧化/抗氧化失衡
Proc Am Thorac Soc. 2005;2(1):50-60. doi: 10.1513/pats.200411-056SF.
5
Antioxidant therapeutic advances in COPD.慢性阻塞性肺疾病的抗氧化治疗进展
Ther Adv Respir Dis. 2008 Dec;2(6):351-74. doi: 10.1177/1753465808098224.
6
Antioxidant therapeutic targets in COPD.慢性阻塞性肺疾病中的抗氧化治疗靶点
Curr Drug Targets. 2006 Jun;7(6):707-20. doi: 10.2174/138945006777435254.
7
Oxidants and COPD.氧化剂与慢性阻塞性肺疾病
Curr Drug Targets Inflamm Allergy. 2005 Dec;4(6):627-41. doi: 10.2174/156801005774912815.
8
Current perspectives of oxidative stress and its measurement in chronic obstructive pulmonary disease.慢性阻塞性肺疾病氧化应激及其检测的研究现状。
COPD. 2010 Aug;7(4):291-306. doi: 10.3109/15412555.2010.496818.
9
COPD: balancing oxidants and antioxidants.慢性阻塞性肺疾病：平衡氧化剂与抗氧化剂
Int J Chron Obstruct Pulmon Dis. 2015 Feb 2;10:261-76. doi: 10.2147/COPD.S42414. eCollection 2015.
10
Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review.靶向氧化应激的小分子治疗慢性阻塞性肺疾病（COPD）的治疗潜力：全面综述。
Molecules. 2022 Aug 28;27(17):5542. doi: 10.3390/molecules27175542.
引用本文的文献
1
The Role of Ferroptosis in Blood-Brain Barrier Injury.铁死亡在血脑屏障损伤中的作用
Cell Mol Neurobiol. 2023 Jan;43(1):223-236. doi: 10.1007/s10571-022-01197-5. Epub 2022 Feb 1.
2
Redox Dysregulation in Aging and COPD: Role of NOX Enzymes and Implications for Antioxidant Strategies.衰老与慢性阻塞性肺疾病中的氧化还原失调：NOX酶的作用及对抗氧化策略的影响
Antioxidants (Basel). 2021 Nov 11;10(11):1799. doi: 10.3390/antiox10111799.
3
Total Antioxidant Status in Stable Chronic Obstructive Pulmonary Disease.稳定期慢性阻塞性肺疾病患者的总抗氧化状态
Int J Chron Obstruct Pulmon Dis. 2020 Oct 6;15:2411-2419. doi: 10.2147/COPD.S264944. eCollection 2020.
4
Four Novel Dammarane-Type Triterpenoids from Pearl Knots of Meyer cv. Silvatica.四种新型达玛烷型三萜类化合物来自 Meyer cv. Silvatica 的珍珠结。
Molecules. 2019 Mar 23;24(6):1159. doi: 10.3390/molecules24061159.
5
Role of GPx3 in PPARγ-induced protection against COPD-associated oxidative stress.GPx3 在 PPARγ 诱导的 COPD 相关氧化应激保护中的作用。
Free Radic Biol Med. 2018 Oct;126:350-357. doi: 10.1016/j.freeradbiomed.2018.08.014. Epub 2018 Aug 15.
6
Crocin attenuates cigarette smoke-induced lung injury and cardiac dysfunction by anti-oxidative effects: the role of Nrf2 antioxidant system in preventing oxidative stress.藏红花通过抗氧化作用减轻香烟烟雾引起的肺损伤和心功能障碍：Nrf2 抗氧化系统在预防氧化应激中的作用。
Respir Res. 2018 Apr 10;19(1):58. doi: 10.1186/s12931-018-0766-3.
7
Proteome analysis of bronchoalveolar lavage from calves infected with bovine respiratory syncytial virus-Insights in pathogenesis and perspectives for new treatments.感染牛呼吸道合胞病毒的犊牛支气管肺泡灌洗蛋白组分析——发病机制见解及新治疗方法展望
PLoS One. 2017 Oct 16;12(10):e0186594. doi: 10.1371/journal.pone.0186594. eCollection 2017.
8
Early decrease of oxidative stress by non-invasive ventilation in patients with acute respiratory failure.无创通气治疗急性呼吸衰竭患者早期降低氧化应激。
Intern Emerg Med. 2018 Mar;13(2):183-190. doi: 10.1007/s11739-017-1750-5. Epub 2017 Sep 15.
9
Steroid Resistant CD8CD28 NKT-Like Pro-inflammatory Cytotoxic Cells in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中类固醇抵抗性CD8CD28自然杀伤T细胞样促炎细胞毒性细胞
Front Immunol. 2016 Dec 19;7:617. doi: 10.3389/fimmu.2016.00617. eCollection 2016.
10
META-ANALYSIS OF CONTINUOUS PHENOTYPES IDENTIFIES A GENE SIGNATURE THAT CORRELATES WITH COPD DISEASE STATUS.连续型表型的荟萃分析确定了与慢性阻塞性肺疾病疾病状态相关的基因特征。
Pac Symp Biocomput. 2017;22:266-275. doi: 10.1142/9789813207813_0026.
本文引用的文献
1
Statin use in COPD patients is associated with a reduction in mortality: a national cohort study.慢性阻塞性肺疾病（COPD）患者使用他汀类药物与死亡率降低相关：一项全国队列研究。
Prim Care Respir J. 2012 Mar;21(1):35-40. doi: 10.4104/pcrj.2011.00095.
2
SIRT1 as a therapeutic target in inflammaging of the pulmonary disease.SIRT1 作为肺部疾病炎症老化的治疗靶点。
Prev Med. 2012 May;54 Suppl(Suppl):S20-8. doi: 10.1016/j.ypmed.2011.11.014. Epub 2011 Dec 8.
3
Sulfiredoxin protein is critical for redox balance and survival of cells exposed to low steady-state levels of H2O2.硫氧还蛋白蛋白对于低稳态水平 H2O2 暴露下的细胞的氧化还原平衡和存活至关重要。
J Biol Chem. 2012 Jan 2;287(1):81-89. doi: 10.1074/jbc.M111.316711. Epub 2011 Nov 15.
4
Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients.通过靶向 Nrf2 使 HDAC2 去硝化作用可恢复 COPD 患者巨噬细胞对糖皮质激素的敏感性。
J Clin Invest. 2011 Nov;121(11):4289-302. doi: 10.1172/JCI45144. Epub 2011 Oct 17.
5
Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice.诱导型一氧化氮合酶抑制逆转了香烟烟雾引起的小鼠肺气肿和肺动脉高压。
Cell. 2011 Oct 14;147(2):293-305. doi: 10.1016/j.cell.2011.08.035.
6
Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease.氧化应激诱导的羰基修饰蛋白抗体与慢性阻塞性肺疾病的严重程度相关。
Am J Respir Crit Care Med. 2011 Oct 1;184(7):796-802. doi: 10.1164/rccm.201010-1605OC.
7
Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan.他汀类药物在慢性阻塞性肺疾病患者中的使用与住院治疗：台湾一项基于全国人群的队列研究。
Clin Ther. 2011 Oct;33(10):1365-70. doi: 10.1016/j.clinthera.2011.08.010. Epub 2011 Oct 2.
8
Beyond neurological disease: new targets for edaravone (Review).超越神经疾病：依达拉奉的新靶点（综述）。
Int J Mol Med. 2011 Dec;28(6):899-906. doi: 10.3892/ijmm.2011.795. Epub 2011 Sep 15.
9
The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development.慢性阻塞性肺疾病治疗的未来——药物研发的困难与障碍。
Lancet. 2011 Sep 10;378(9795):1027-37. doi: 10.1016/S0140-6736(11)61047-7.
10
New insights into the immunology of chronic obstructive pulmonary disease.慢性阻塞性肺疾病免疫学的新见解。
Lancet. 2011 Sep 10;378(9795):1015-26. doi: 10.1016/S0140-6736(11)60988-4.
Zotero 插件